1. Volume 45, Issue 5, Pages 620-627 (May 2004)
5-Alpha Reductase Inhibition Provides Superior Benefits to Alpha Blockade by Preventing AUR and BPH-Related Surgery 
P. Boyle, C. Roehrborn, R. Harkaway, J. Logie, J. de la Rosette, M. Emberton 
European Urology 
Volume 45, Issue 5, Pages (May 2004)
DOI: /j.eururo

2. Fig. 1
Percentage frequency of patients treated with either a 5ARI (red bars) or an alpha-blocker (blue bars). Figures refer to the percentage of all patients receiving a treatment that fell within the defined age group on the date of first prescription. The numbers of men within each age and treatment group are given in Table 1.
European Urology  , DOI: ( /j.eururo )

3. Fig. 2
Unadjusted Kaplan–Meier “survival” from first treatment to surgery or AUR, by first treatment. All surgery or AUR events occurring before a change in therapy are attributed to the preceding treatment.
European Urology  , DOI: ( /j.eururo )

4. Fig. 3
Adjusted hazard ratios (with 95% confidence intervals ) for the interval from first treatment to disease progression. The lines represent the hazard ratios for patients receiving alpha-blockers, relative to the reference category of 5ARIs. A hazard ratio greater than one indicates that the interval to disease progression is short relative to the reference, with the difference between drug class being significant if the confidence intervals exclude one. Open circles represent the point estimates from analyses including all events, squares represent the point estimates from analyses including only events occurring during treatment or within the following four weeks (see methods). Figures for surgery/AUR combined are from Cox proportional hazards models following patients to the first event from either surgery or AUR. Figures for surgery alone or AUR alone, are from competing risks models considering surgery and AUR as separate and distinct outcomes.
European Urology  , DOI: ( /j.eururo )